CLAIMS

What is claimed is:

1. Use of a casein hydrolysate in the manufacture of a composition for treating an inflammatory disease in a subject, wherein the hydrolysate consists of peptides with a molecular weight of more than 500 Da, wherein the hydrolysate comprises each of the following individual peptides: SEQ ID NO 4, SEQ ID NO 13, SEQ ID NO 17, SEQ ID NO 21, SEQ ID NO 24, SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 32, SEQ ID NO 51, SEQ ID NO 57, SEQ ID NO 60, and SEQ ID NO 63, and further wherein the hydrolysate is to be administered in a nutritional composition comprising 0.1 to 1 g/100 kcal of a prebiotic composition, wherein the prebiotic composition comprises at least 20% of an oligosaccharide.

2. The use according to claim 1, wherein the inflammatory disease is selected from the group consisting of type 1 diabetes, Crohn's disease, Ulcerative colitis, Metabolic syndrome, and Celiac disease.

3. The use according to claim 1, wherein the hydrolysate comprises at least three additional individual peptides selected from the group consisting of SEQ ID NO 1-3, SEQ ID NO 5-12, SEQ ID NO 14-16, SEQ ID NO 18-20, SEQ ID NO 22-23, SEQ ID NO 25-29, SEQ ID NO 33-50, SEQ ID NO 52-56, SEQ ID NO 58-59, SEQ ID NO 61-62, and SEQ ID NO 64.

4. The use according to claim 3, wherein the hydrolysate comprises at least three additional individual peptides selected from the group consisting of SEQ ID NO 1-3, SEQ ID NO 5-12, SEQ ID NO 14-16, SEQ ID NO 18-20, SEQ ID NO 22-23.

5. The use according to claim 4, wherein the hydrolysate comprises at least three additional individual peptides selected from the group consisting of SEQ ID NO 1-3, SEQ ID NO 5-12, SEQ ID NO 14-16.

6. The use according to claim 1, wherein the nutritional composition further comprises a lipid or a fat phase, and a protein source.

7. The use according to claim 6, wherein, the nutritional composition further comprises 5 to 100 mg/100 kcal of a source of long chain polyunsaturated fatty acids which comprises docosahexanoic acid.

8. The use according to claim 7, wherein the nutritional composition further comprises arachidonic acid.

9. The use according to claim 1, wherein the subject is a human child or juvenile.

10. The use according to claim 1, wherein the nutritional formulation additionally comprises one or more of carbohydrates, nucleic acids, lipids, minerals, anabolic nutrients, vitamins, antioxidants, probiotic bacterial strains and lipotropic agents.